Time filter

Source Type

Nakanishi K.,Komaki City Hospital | Kobayashi D.,Nagoya University | Mochizuki Y.,Komaki City Hospital | Ishigure K.,Konan Kosei Hospital | And 7 more authors.
International Journal of Clinical Oncology | Year: 2016

Background: The aim of this study was to explore whether a combination of S-1 and paclitaxel offers any benefit over paclitaxel alone to patients pretreated by S-1. Methods: Gastric cancer patients who developed progression during S-1-based first-line chemotherapy or had recurrence during postoperative adjuvant chemotherapy by S-1 were randomly assigned to receive second-line treatment either by weekly administration of paclitaxel at 80 mg/m2 three times every 4 weeks or daily oral S-1 (80 mg/m2) for 2 weeks plus paclitaxel (50 mg/m2) given on days 1 and 8, every 3 weeks (S-1 plus paclitaxel). The primary endpoint was progression-free survival (PFS) at 4 months after the initiation of treatment. Results: A total of 78 patients were eligible for efficacy analyses—40 were assigned to the paclitaxel group and 38 to the S-1 plus paclitaxel group. PFS at 4 months was similar between the groups (50 % for paclitaxel vs 55 % for S-1 plus paclitaxel, P = 0.641). There were no differences between the groups either in progression-free survival (4.6 vs 4.6 months, respectively, P = 0.526), overall survival (10.0 vs 10.0 months, respectively, P = 0.464), or overall response rate (27 vs 22 %, respectively, P = 0.767). The incidences of grade 3 or 4 hematological and non-hematological toxicities were also equivalent between the two groups (25 vs 26 % and 24 vs 26 %, respectively). Conclusions: No benefit of S-1 administration beyond progression was shown when paclitaxel was selected as the key drug for second-line chemotherapy. © 2015, Japan Society of Clinical Oncology. Source

Nakashima M.,Nagoya University | Sakai T.,Nagoya University | Hiraiwa H.,Nagoya University | Hamada T.,Nagoya University | And 10 more authors.
Biochemical and Biophysical Research Communications | Year: 2012

S100A12 is a member of the S100 protein family, which are intracellular calcium-binding proteins. Although there are many reports on the involvement of S100A12 in inflammatory diseases, its presence in osteoarthritic cartilage has not been reported. The purpose of this study was to investigate the expression of S100A12 in human articular cartilage in osteoarthritis (OA) and to evaluate the role of S100A12 in human OA chondrocytes. We analyzed S100A12 expression by immunohistochemical staining of cartilage samples obtained from OA and non-OA patients. In addition, chondrocytes were isolated from knee cartilage of OA patients and treated with recombinant human S100A12. Real-time RT-PCR was performed to analyze mRNA expression. Protein production of matrix metalloproteinase 13 (MMP-13) and vascular endothelial growth factor (VEGF) in the culture medium were measured by ELISA. Immunohistochemical analyses revealed that S100A12 expression was markedly increased in OA cartilages. Protein production and mRNA expression of MMP-13 and VEGF in cultured OA chondrocytes were significantly increased by treatment with exogenous S100A12. These increases in mRNA expression and protein production were suppressed by administration of soluble receptor for advanced glycation end products (RAGE). Both p38 mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB) inhibitors also suppressed the increases in mRNA expression and protein production of MMP-13 and VEGF. We demonstrated marked up-regulation of S100A12 expression in human OA cartilages. Exogenous S100A12 increased the production of MMP-13 and VEGF in human OA chondrocytes. Our data indicate the possible involvement of S100A12 in the development of OA by up-regulating MMP-13 and VEGF via p38 MAPK and NF-κB pathways. © 2012 Elsevier Inc. Source

Sawasaki K.,Hamamatsu Medical Center | Sato T.,Hamamatsu Medical Center | Takayama Y.,Hamamatsu Medical Center | Yokota S.,Hamamatsu Medical Center | And 5 more authors.
Journal of Arrhythmia | Year: 2012

Introduction: Surgical procedures for pacemaker implantation vary among facilities. The extrathoracic venous puncture method has been utilized for lead insertion, although patients' body movements can displace the targeted vein from the area into which a contrast agent has been injected for imaging. Failed punctures cause edema around the puncture site, spasm, or venous collapse due to bleeding, which may render another puncture impractical. To overcome these problems, we report a new technique for the extrathoracic puncture method. Methods and results: From April 2007 through March 2011, we performed 35 new dual chamber pacemaker implantation procedures. This study compared a conventional puncture group (from April 2007 through March 2009; Group A) with a catheter-guided puncture group (from April 2009 through March 2011; Group B). We analyzed procedure time and procedure-related complications in each group. The procedure time was 138.6 ± 41.8 min in the conventional puncture group (Group A) and 109.8 ± 23.2 in the catheter-guided puncture group (Group B). There was a significant reduction in the procedure time in the catheter-guided puncture group (Group B) compared with the conventional puncture group (Group A; p=0.016). No patients in either group had pneumothorax, hematoma, or any other complications. Conclusion: Our puncture method involving catheter insertion appears to be safe and effective. © 2012 Japanese Heart Rhythm Society. Source

Horio J.,Nagoya University | Takai Y.,Nagoya University | Iwata E.,Nishio Municipal Hospital | Iwase C.,Nagoya University | And 3 more authors.
Japanese Journal of Clinical Ophthalmology | Year: 2016

Purpose: To reveal the influence of anticoagulants/antiplatelets on the strabismus surgery. Subjects and Methods: Ten patients in Nagoya University Hospital, seven male and three female, were taking anticoagulants/antiplatelets and had undergone rectus muscle recession/resection procedures under local anesthesia during the period of August 2011-March 2015. The mean age of participants were 65.1-10.4 years old. Operation time, anti-thrombotic medication, international normalized ratioprothrombin time (PT-INR), perioperative hemorrhagic complication were extracted from clinical records. Results: Before operation, five patients withdrawn antiplatelets, one patient who was at higher risk of infarction used heparin sodium as a replacement for anticoagulants, another patient used dalteparin sodium to replace antiplatelet, two patients taking antiplatelets and one patient taking anticoagulant did not withdraw. During the perioperative period, no remarkable ocular and general complications were found even if the medications were withdrawn, except for one patient who was using ethyl icosapentate for hypertension, who visited the emergency room after surgery because of severe subconjunctival hemorrhage. Mild hemorrhage was observed in all patients. Mean PT-INR one week before operation was 1.6 ± 0.2 (n = 2) for who anticoagulants group and 0.98 ± 0.07 (n = 8) for antiplatelets group. Conclusions: Any severe complications were not observed. Source

Muramatsu H.,Red Cross | Hayashi M.,Red Cross | Hamazima A.,Gunma Childrens Medical Center | Tomizuka Y.,Social Insurance Funabashi Central Hospital | And 4 more authors.
Japanese Journal of Plastic Surgery | Year: 2013

In 2009, the first tissue-engineered cellular product in Japan, autologous cultured epidermis "JACE", manufactured by Japan Tissue Engineering Co., Ltd (J-TEC) was approved by the Ministry of Health, Labour, and Welfare. Since then we have treated a large number of total body surface area (TBSA) patients with this new product. Initially, we based our treatment on the suggested protocol by J-TEC, which resulted in a poor take rate. Therefore, we have established our own protocol for the treatment of TBSA patients. In this new protocol, we start with early tangential excision and coverage with an artificial dermis, followed by the placement of cultured epithelial autograft (CEA) on a 6: 1 meshed autograft and controlled on the dry side. This method has produced an excellent take rate for CEA, which has significantly increased the survival rate, shortening admission days, and improved the activities of daily living after hospital discharge. Source

Discover hidden collaborations